Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies.

Ruck T, Bittner S, Afzali AM, Göbel K, Glumm S, Kraft P, Sommer C, Kleinschnitz C, Preuße C, Stenzel W, Wiendl H, Meuth SG.

Oncotarget. 2015 Dec 22;6(41):43230-43. doi: 10.18632/oncotarget.6462.

2.

Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.

Basher F, Jeng EK, Wong H, Wu J.

Oncotarget. 2016 Jan 5;7(1):814-30. doi: 10.18632/oncotarget.6416.

3.

An approach to the immunophenotypic features of circulating CD4⁺NKG2D⁺ T cells in invasive cervical carcinoma.

Garcia-Chagollan M, Jave-Suarez LF, Haramati J, Bueno-Topete MR, Aguilar-Lemarroy A, Estrada-Chavez C, Bastidas-Ramirez BE, Pereira-Suarez AL, Del Toro-Arreola S.

J Biomed Sci. 2015 Oct 20;22:91. doi: 10.1186/s12929-015-0190-7.

4.

Lymphocytic Choriomeningitis Virus Expands a Population of NKG2D+CD8+ T Cells That Exacerbates Disease in Mice Coinfected with Leishmania major.

Crosby EJ, Clark M, Novais FO, Wherry EJ, Scott P.

J Immunol. 2015 Oct 1;195(7):3301-10. doi: 10.4049/jimmunol.1500855. Epub 2015 Aug 19.

PMID:
26290604
5.

NKG2D Receptor and Its Ligands in Host Defense.

Lanier LL.

Cancer Immunol Res. 2015 Jun;3(6):575-82. doi: 10.1158/2326-6066.CIR-15-0098. Review.

6.

Adenovirus serotype 5 E1A expressing tumor cells elicit a tumor-specific CD8+ T cell response independent of NKG2D.

Korrer MJ, Routes JM.

Results Immunol. 2015 Jan 15;5:1-5. doi: 10.1016/j.rinim.2015.01.001. eCollection 2015.

7.

Immunohistochemical validation and expression profiling of NKG2D ligands in a wide spectrum of human epithelial neoplasms.

Fujita H, Hatanaka Y, Sutoh Y, Suzuki Y, Oba K, Hatanaka KC, Mitsuhashi T, Otsuka N, Fugo K, Kasahara M, Matsuno Y.

J Histochem Cytochem. 2015 Mar;63(3):217-27. doi: 10.1369/0022155414563800. Epub 2014 Dec 3.

8.

CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors.

Hu J, Zhu S, Xia X, Zhang L, Kleinerman ES, Li S.

Mol Cancer. 2014 Feb 24;13:34. doi: 10.1186/1476-4598-13-34.

9.

Modulation of NKG2D expression in human CD8(+) T cells corresponding with tuberculosis drug cure.

Hassan SS, Cho JE, Akram M, Fielding KL, Dockrell HM, Cliff JM.

PLoS One. 2013 Jul 26;8(7):e70063. doi: 10.1371/journal.pone.0070063. Print 2013.

10.

CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling.

Hosomi S, Chen Z, Baker K, Chen L, Huang YH, Olszak T, Zeissig S, Wang JH, Mandelboim O, Beauchemin N, Lanier LL, Blumberg RS.

Eur J Immunol. 2013 Sep;43(9):2473-83. doi: 10.1002/eji.201242676. Epub 2013 Jun 18.

11.

MICA variant promotes allosensitization after kidney transplantation.

Tonnerre P, Gérard N, Chatelais M, Poli C, Allard S, Cury S, Bressollette C, Cesbron-Gautier A, Charreau B.

J Am Soc Nephrol. 2013 May;24(6):954-66. doi: 10.1681/ASN.2012080814. Epub 2013 Mar 28.

12.

Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response.

Slavuljica I, Krmpotić A, Jonjić S.

Front Immunol. 2011 Dec 28;2:85. doi: 10.3389/fimmu.2011.00085. eCollection 2011.

13.

RAE1ε ligand expressed on pancreatic islets recruits NKG2D receptor-expressing cytotoxic T cells independent of T cell receptor recognition.

Markiewicz MA, Wise EL, Buchwald ZS, Pinto AK, Zafirova B, Polic B, Shaw AS.

Immunity. 2012 Jan 27;36(1):132-41. doi: 10.1016/j.immuni.2011.11.014. Epub 2012 Jan 12.

14.

NF-κB regulates MICA gene transcription in endothelial cell through a genetically inhibitable control site.

Lin D, Lavender H, Soilleux EJ, O'Callaghan CA.

J Biol Chem. 2012 Feb 3;287(6):4299-310. doi: 10.1074/jbc.M111.282152. Epub 2011 Dec 14.

15.

NKG2D receptor regulates human effector T-cell cytokine production.

Barber A, Sentman CL.

Blood. 2011 Jun 16;117(24):6571-81. doi: 10.1182/blood-2011-01-329417. Epub 2011 Apr 25.

16.

Studies on the antigenicity of the NKG2D ligand H60a in tumour cells.

Yadav D, Ngolab J, Dang N, Bui JD.

Immunology. 2011 Jun;133(2):197-205. doi: 10.1111/j.1365-2567.2011.03427.x. Epub 2011 Mar 25.

17.

Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis.

Lünemann A, Tackenberg B, DeAngelis T, da Silva RB, Messmer B, Vanoaica LD, Miller A, Apatoff B, Lublin FD, Lünemann JD, Münz C.

Int Immunol. 2011 Feb;23(2):139-48. doi: 10.1093/intimm/dxq463. Epub 2011 Jan 6.

18.

NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.

Hanaoka N, Jabri B, Dai Z, Ciszewski C, Stevens AM, Yee C, Nakakuma H, Spies T, Groh V.

J Immunol. 2010 Nov 15;185(10):5732-42. doi: 10.4049/jimmunol.1002092. Epub 2010 Oct 6.

19.

Functional dichotomy between NKG2D and CD28-mediated co-stimulation in human CD8+ T cells.

Rajasekaran K, Xiong V, Fong L, Gorski J, Malarkannan S.

PLoS One. 2010 Sep 9;5(9). pii: e12635. doi: 10.1371/journal.pone.0012635.

20.

Effect of NKG2D ligand expression on host immune responses.

Champsaur M, Lanier LL.

Immunol Rev. 2010 May;235(1):267-85. doi: 10.1111/j.0105-2896.2010.00893.x. Review.

Items per page

Supplemental Content

Write to the Help Desk